Patents Assigned to Genentech
  • Prevention and treatment of complement-associated eye conditions
    Patent number: 8497094
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: July 30, 2013
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, Jr., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS
    Publication number: 20130190356
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, A, B, C, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Application
    Filed: December 18, 2012
    Publication date: July 25, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genetech, Inc.
  • BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS
    Publication number: 20130190288
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, A, X1, X2, X3, X4, R1, R2, R3a, R3b, R4a and R4b are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Application
    Filed: December 18, 2012
    Publication date: July 25, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • Anti-VEGF antibodies
    Patent number: 8492527
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: July 23, 2013
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic A. Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • Nucleic acids encoding humanized anti-CD40 antibodies
    Patent number: 8492531
    Abstract: Provided are humanized anti-CD40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of CD40 antigen.
    Type: Grant
    Filed: September 19, 2012
    Date of Patent: July 23, 2013
    Assignee: Genentech, Inc.
    Inventors: Leonard Presta, Lori Y. O'Connell
  • Isoindolones derivatives as MEK kinase inhibitors and methods of use
    Patent number: 8492427
    Abstract: The invention relates to isoindolones of formula, (I) with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: July 1, 2009
    Date of Patent: July 23, 2013
    Assignee: Genentech, Inc.
    Inventors: Emanuela Gancia, Robert Andrew Heald, Philip Jackson, Stephen Price
  • ANTI-LRP5 ANTIBODIES AND METHODS OF USE
    Publication number: 20130183320
    Abstract: The invention provides anti-LRP5 antibodies and methods of making and using the same.
    Type: Application
    Filed: January 18, 2013
    Publication date: July 18, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • METHODS OF USING FGF19 MODULATORS
    Publication number: 20130183294
    Abstract: Provided herein are methods of using FGF19 modulators and/or bile acid metabolism biomarkers.
    Type: Application
    Filed: January 18, 2013
    Publication date: July 18, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • Anti-VEGF-C antibodies and methods using same
    Patent number: 8486397
    Abstract: The invention provides VEGF-C antagonists, such as anti-VEGF-C antibodies, and their use in the prevention and treatment of tumor progression.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: July 16, 2013
    Assignee: Genentech, Inc.
    Inventors: Anil D. Bagri, Germaine Fuh, Chingwei V. Lee
  • Azaindolizines and methods of use
    Patent number: 8486963
    Abstract: The invention relates to azaindolizines of formula I-a or I-b with anti-cancer and/or anti-inflammatory activity and more specifically to azaindolizines which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: July 16, 2013
    Assignee: Genentech, Inc.
    Inventors: Stephen Price, Robert Heald, Peter Hewitt
  • SERINE/THREONINE KINASE INHIBITORS
    Publication number: 20130178486
    Abstract: Compounds having the formula I wherein A, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, Ra, Rb, X1, X2, X3 and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
    Type: Application
    Filed: December 21, 2012
    Publication date: July 11, 2013
    Applicant: Genentech, Inc.
    Inventor: Genentech, Inc.
  • Mutant smoothened and methods of using the same
    Patent number: 8481680
    Abstract: The emergence of mutations in tyrosine kinases following treatment of cancer patients with molecular-targeted therapy represents a major mechanism of acquired drug resistance. Here, we describe a mutation in the serpentine receptor, Smoothened (SMO), which results in resistance to a Hedgehog (Hh) pathway inhibitor in medulloblastoma. A single amino acid substitution in a conserved glutamic acid residue of SMO maintains Hh signaling, but results in the inability of the Hh pathway inhibitor, GDC-0449, to bind SMO and suppress the pathway. The invention provides screening methods to detect SMO mutations and methods to screen for drugs that specifically modulate mutant SMO exhibiting drug resistance.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: July 9, 2013
    Assignees: Genentech, Inc., Curis, Inc.
    Inventors: Frederic J. de Sauvage, Gerrit J. P. Dijkgraaf
  • Inhibitors Of Complement Activation
    Publication number: 20130171155
    Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.
    Type: Application
    Filed: February 5, 2013
    Publication date: July 4, 2013
    Applicant: GENENTECH, INC.
    Inventor: GENENTECH, INC.
  • ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR
    Publication number: 20130171170
    Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.
    Type: Application
    Filed: June 12, 2012
    Publication date: July 4, 2013
    Applicant: GENENTECH, INC.
    Inventors: ALLEN J. EBENS, JR., ALANE M. GRAY, WEI-CHING LIANG, YAN WU, SHANG-FAN YU
  • INHIBITORS OF IAP
    Publication number: 20130172264
    Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1,R2,R3,R4,R5 and R6 are as described herein.
    Type: Application
    Filed: January 3, 2013
    Publication date: July 4, 2013
    Applicant: GENENTECH, INC.
    Inventor: GENENTECH, INC.
  • Humanized Anti-Factor D Antibodies And Uses Thereof
    Publication number: 20130171070
    Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: February 5, 2013
    Publication date: July 4, 2013
    Applicant: Genentech, Inc.
    Inventor: Genentech, Inc.
  • METHOD OF TREATING HUMAN GROWTH HORMONE MEDIATED CONDITION
    Publication number: 20130165378
    Abstract: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.
    Type: Application
    Filed: February 21, 2013
    Publication date: June 27, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • APO-2 LIGAND/TRAIL VARIANTS AND USES THEREOF
    Publication number: 20130165383
    Abstract: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided. In addition, therapeutic methods for using Apo-2 ligand variant polypeptides are provided.
    Type: Application
    Filed: April 6, 2012
    Publication date: June 27, 2013
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Sarah Hymowitz
  • HUMANIZED ANTIBODY
    Publication number: 20130164278
    Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
    Type: Application
    Filed: August 7, 2012
    Publication date: June 27, 2013
    Applicants: Genentech, Inc., AC Immune S.A.
    Inventors: Andrea Pfeifer, Maria Pihtgren, Andreas Muhs, Ryan Watts
  • Apo-2 ligand/trail formulations
    Patent number: 8470969
    Abstract: The present invention relates generally to Apo2L/TRAIL purification involving crystallization.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: June 25, 2013
    Assignee: Genentech, Inc.
    Inventors: Heather Flores, Tanya P. Lin, Timothy C. Matthews, Roger Pai, Zahra Shahrokh, Evan E. Shave, Patricia A. Rancatore